Gilead to Pay Investors $1.8 Million in Fees Over Truvada Files

Gilead Sciences Inc. must turn over $1.8 million in legal costs and fees to the investors who sued it for records involving its blockbuster HIV drugs, a Delaware judge ruled Thursday, saying Gilead crossed the “fine line between glaringly egregious conduct and an aggressive litigation position.”

After the pharmaceutical company “declined to produce a single document to any of the five plaintiffs thereby forcing them to commence litigation,” it “took a series of positions during litigation that, when viewed collectively, were glaringly egregious,” Chancellor Kathaleen S. McCormick wrote.

The ruling for Delaware’s Chancery Court comes about eight months after McCormick—then ...